Risk prediction in acute coronary syndrome from serial in-hospital measurements of N-terminal pro-B-type natriuretic peptide

References

• Richards AM, Doughty R, Nicholls MG, MacMahon S, Ikram H, Sharpe N, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand heart failure group. Circulation 1999; 99: 786–92
   PubMed Web of Science ®Google Scholar
• Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005; 352: 666–75
   PubMed Web of Science ®Google Scholar
• Hong SN, Ahn Y, Yoon NS, Lee KH, Kim YS, Hwang SH, et al. Usefulness of serum N-terminal pro-brain natriuretic peptide to predict in-stent restenosis in patients with preserved left ventricular function and normal troponin I levels. Am J Cardiol. 2007; 99: 1051–4
   PubMedGoogle Scholar
• de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345: 1014–21
   PubMed Web of Science ®Google Scholar
• Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106: 2913–8
   PubMed Web of Science ®Google Scholar
• Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002; 40: 437–45
   PubMed Web of Science ®Google Scholar
• Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF, Maggioni AP, et al. C. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004; 110: 128–34
   PubMedGoogle Scholar
• Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003; 41: 1264–72
   PubMed Web of Science ®Google Scholar
• James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-B-type natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial myocardial infarction in patients with unstable coronary artery disease: A global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108: 275–81
   PubMed Web of Science ®Google Scholar
• Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfelt G, Lagerquist B, et al. N-terminal pro brain natriuretic peptide in relation to inflammation, myocardial necrosis and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol. 2003; 42: 1909–16
   PubMed Web of Science ®Google Scholar
• Heeschen C, Hamm CW, Mitrovic V, Lantelme N-H, White HD, for the Platelet Receptor Inhibition in Ischemic Syndrome management (PRISM) investigators. N-terminal pro-b-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes Circulation 2004;110:3206–12.
   PubMed Web of Science ®Google Scholar
• Lindahl B, Lindback J, Jernberg T, Johnston N, Stridsberg M, Venge P, et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment-elevation acute coronary syndromes. J Am Coll Cardiol. 2005; 45: 533–41
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, et al. for the A to Z Investigators. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. J Am Med Ass. 2005; 294: 2866–71
   Google Scholar
• Palazzuoli A, Deckers J, Calabro A, Campagna MS, Nuti R, Pastorelli M, et al. Brain natriuretic peptide and other risk markers for outcome assessment in patients with non-ST-elevation coronary syndromes and preserved systolic function. Am J Cardiol. 2006; 98: 1322–8
   PubMed Web of Science ®Google Scholar
• Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82–91
   PubMed Web of Science ®Google Scholar
• Talwar S, Squire IB, Downie PF, McCullough AM, Campton MC, Davies JE, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction. Correlation with left ventricular systolic dysfunction. Eur Heart J. 2000; 21: 514–21
   Google Scholar
• Björklund E, Jernberg T, Johansen P, Venge P, Dellborg M, Wallentin L, et al. Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction. Heart 2006; 92: 735–40
   PubMedGoogle Scholar
• Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991; 87: 1402–12
   PubMed Web of Science ®Google Scholar
• Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and in patients with heart failure. Circulation 1994; 90: 195–203
   PubMed Web of Science ®Google Scholar
• Riezebos RK, Ronner E, de Boer BA, Slaats EH, Tijssen JGP, Laarman G-J. Dynamics in N-terminal pro-brain natriuretic peptide concentration in patients with non-ST-elevation acute coronary syndrome. Am Heart J. 2005; 150: 1255–9
   PubMedGoogle Scholar
• Jaffe AS, Katus H. Acute coronary syndrome biomarkers: the need for more adequate reporting. Circulation 2004; 110: 104–6
   PubMed Web of Science ®Google Scholar
• Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. A low-molecular-weight, selective thrombin inhibitor, inogatran, versus heparin in unstable coronary artery disease in 1209 patients. A double blind, randomised, dose-finding study. Eur Heart J. 1997;18:1416–25.
   PubMedGoogle Scholar
• Müller-Bardoff M, Hallermeyer K, Schröder A, Ebert C, Borgya A, Gerhardt W, et al. Improved troponin T ELISA specific for troponin T isoform: assay and development and analytical and clinical validation. Clin Chem. 1997; 43: 458–66
   PubMedGoogle Scholar
• Schemper M, Smith TL. Efficient evaluation of treatment effects in the presence of missing covariate values. Stat Med. 1990; 9: 777–84
   PubMed Web of Science ®Google Scholar
• Schemper M, Heinze G R. Revisited for prognostic factor studies. Stat Med. 1997; 16: 73–80
   PubMed Web of Science ®Google Scholar
• Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, et al. Rapid Ventricular Induction of Brain Natriuretic Peptide Gene Expression in Experimental Acute Myocardial Infarction. Circulation 1995; 92: 1558–64
   PubMed Web of Science ®Google Scholar
• Rao AC, Collison PO, Canepa-Anson R, Joseph SP. Troponin T measurement after myocardial infarction can identify left ventricular ejection of less than 40%. Heart 1998; 80: 223–5
   PubMedGoogle Scholar
• Kyriakides ZS, Markianos M, Michalis L, Antoniadis A, Nikolaou NI, Kremastinos DT. Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin Cardiol. 2000; 23: 285–8
   PubMedGoogle Scholar
• Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischemia induced by dynamic exercise in patients with angina pectoris. Clin Sci. 1995; 88: 551–6
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004; 44: 1988–95
   PubMed Web of Science ®Google Scholar
• Toth M, Vuorinen KH, Vuolteenaho O, Hassinen IE, Uusimaa PA, Leppaluoto J, et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol. 1994; 266: H1572–80
   PubMedGoogle Scholar
• Fung JW, Yu CM, Yip G, Chan S, Yandle TG, Richards AM, et al. Effects of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol. 2003; 92: 406–10
   PubMedGoogle Scholar
• Jernberg T, Venge P, Lindahl B. Comparison between second and third generation troponin T assay in patients with symptoms suggestive of an acute coronary syndrome but without ST segment elevation. Cardiology 2003; 100: 29–35
   PubMedGoogle Scholar